BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ofatumumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ofatumumab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05090371-6493@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:Ofatumumab: Phase 4 readout est. (NCT05090371)
DESCRIPTION:Ofatumumab\, phase 4\, Multiple Sclerosis.\nStudy: A Multicente
 r Study of Continued Current Therapy vs Transition to Ofatumumab After Neu
 rofilament (NfL) Elevation\nEstimated primary completion: 13 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ofatumumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05090371
URL:https://assetmemo.bio/drug/ofatumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871006-6493@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ofatumumab: Phase 1/2 readout est. (NCT07871006)
DESCRIPTION:Ofatumumab\, phase 1/2.\nStudy: Ofatumumab in Treatment-Refract
 ory¬ Narcolepsy Type 1\nEstimated primary completion: 30 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ofatumumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07871006
URL:https://assetmemo.bio/drug/ofatumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546110-6493@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Ofatumumab: Phase 1 readout est. (NCT07546110)
DESCRIPTION:Ofatumumab\, phase 1\, Multiple Sclerosis.\nStudy: An Open-Labe
 l\, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Effic
 acy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the 
 Treatment of Multiple Sclerosis (MS).\nEstimated primary completion: 30 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ofatumum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7546110
URL:https://assetmemo.bio/drug/ofatumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03650114-6493@assetmemo.bio
DTSTAMP:20261121T005416Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ofatumumab: Phase 3 readout est. (NCT03650114)
DESCRIPTION:Ofatumumab\, phase 3\, Multiple Sclerosis.\nStudy: Long-term Sa
 fety\, Tolerability and Effectiveness Study of Ofatumumab in Patients With
  Relapsing MS\nEstimated primary completion: 30 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ofatumumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03650114
URL:https://assetmemo.bio/drug/ofatumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
